Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study


  • Marieke M.B. Seyger Department of Dermatology, Radboud University Nijmegen Medical Centre, NL-6500 HB Nijmegen, the Netherlands
  • Matthias Augustin
  • Michael Sticherling
  • Teresa Bachhuber
  • Juanzhi Fang
  • James Hetherington
  • James Lucas
  • Sophie Meakin
  • Craig Richardson
  • Amy S. Paller



psoriasis, paediatric psoriasis, point-in-time survey, real-world, clinical characteristics, unmet needs


This study is a retrospective analysis using data collected from the Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey. Despite being treated for their psoriasis, a substantial proportion of paediatric patients presented with moderate (18.3%) or severe (1.3%) disease at sampling; 42.9% and 92.0% had a body surface area (BSA) of >10%, and 38.8% and 100.0% had a Psoriasis Area Severity Index (PASI) score >10, respectively. Overall, 69.9% of patients had only ever been treated with a topical therapy for their psoriasis. For patients with moderate or severe disease at sampling, 16.3% and 14.4% were currently receiving conventional systemics or biologic therapy, respectively. There is a clinical unmet need in this paediatric population; a considerable percentage of patients still experienced moderate or severe disease and persistent psoriasis symptoms, with numerous body areas affected. A significant proportion of patients were undertreated, which may explain the high burden of disease observed.


Download data is not yet available.


Lansang P, Bergman JN, Fiorillo L, Joseph M, Lara-Corrales I, Marcoux D, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol 2020; 82: 213-221. DOI:

de Jager ME, De Jong EM, Evers AW, Van De Kerkhof PC, Seyger MM. The burden of childhood psoriasis. Pediatr Dermatol 2011; 28: 736-737. DOI:

Eisert L, Augustin M, Bach S, Dittmann M, Eiler R, Folster-Holst R, et al. S2k guidelines for the treatment of psoriasis in children and adolescents - short version part 2. J Dtsch Dermatol Ges 2019; 17: 959-973. DOI:

Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol 2020; 82: 161-201. DOI:

de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62: 1013-1030. DOI:

Bronckers I, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol 2017; 153: 1147-1157. DOI:

Bulbul Baskan E, Yazici S, Tunali S, Saricaoglu H. Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis. J Dermatolog Treat 2016; 27: 328-331. DOI:

Dogra S, Mahajan R, Narang T, Handa S. Systemic cyclosporine treatment in severe childhood psoriasis: a retrospective chart review. J Dermatolog Treat 2017; 28: 18-20. DOI:

Pereira TM, Vieira AP, Fernandes JC, Sousa-Basto A. Cyclosporin A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 651-656. DOI:

Hamm H, Wilsmann-Theis D, Tsianakas A, Gambichler T, Taipale K, Lauterbach J, et al. Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial. Br J Dermatol 2021; 185: 62-73. DOI:

Subedi S, Yu Q, Chen Z, Shi Y. Management of pediatric psoriasis with acitretin: a review. Dermatol Ther 2018; 31: doi: 10.1111/dth.12571. DOI:

D'Adamio S, Silvaggio D, Massaro A, Lombardo P, Bianchi L, Talamonti M, et al. Pharmacotherapeutic management of psoriasis in adolescents and children. Expert Opin Pharmacother 2019; 20: 1777-1785. DOI:

Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol 2021; 35: 938-947. DOI:

Paller AS, Seyger MMB, Alejandro Magarinos G, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol 2020; 183: 231-241. DOI:

Libon F, Lebas E, De Schaetzen V, Sabatiello M, De Schepper S, Nikkels AF. Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients. Expert Rev Clin Immunol 2021; 17: 947-955. DOI:

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol 2015; 29: 425-437. DOI:

de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. Br J Dermatol 2010; 163: 1099-1101. DOI:

Arese V, Albini P, Ibba F, Panzone M, Cervetti O. Juvenile psoriasis: an epidemiological study of 69 cases. G Ital Dermatol Venereol 2018; 153: 469-472. DOI:

Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guerin A, et al. Prevalence of psoriasis in children and adolescents in the united states: a claims-based analysis. J Drugs Dermatol 2018; 17: 187-194.

Edson-Heredia E, Anderson S, Guo J, Zhu B, Malatestinic WN, Wine-Lee L, et al. Real-world claims analyses of comorbidity burden, treatment pattern, healthcare resource utilization, and costs in pediatric psoriasis. Adv Ther 2021; 38: 3948-3961. DOI:

Mahe E, Beauchet A, Bodemer C, Phan A, Bursztejn AC, Boralevi F, et al. Psoriasis and obesity in French children: a case-control, multicentre study. Br J Dermatol 2015; 172: 1593-1600. DOI:

Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020; 82: 117-122. DOI:

Salman A, Yucelten AD, Sarac E, Saricam MH, Perdahli-Fis N. Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study. An Bras Dermatol 2018; 93: 819-823. DOI:

Pinter A, Mielke N, Malisiewicz B, Kaufmann R, Konig A. Management of paediatric psoriasis by paediatricians: a questionnaire-based survey. Dermatol Ther (Heidelb) 2020; 10: 671-680. DOI:

Nelson PA, Chew-Graham CA, Griffiths CE, Cordingley L, Team I. Recognition of need in health care consultations: a qualitative study of people with psoriasis. Br J Dermatol 2013; 168: 354-361. DOI:

Simpson JK, Wilson M, Ahmed AA, Mizara A, Clarke A, McBride SR. An exploratory study using framework analysis to investigate health-seeking behaviour in patients with psoriasis. Br J Dermatol 2017; 177: 742-750. DOI:

Wade AG, Crawford GM, Young D, Leman J, Pumford N. Severity and management of psoriasis within primary care. BMC Fam Pract 2016; 17: 145. DOI:

Bruins FM, Bronckers I, Cai R, Groenewoud JMM, Krol M, de Jong E, et al. Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients. Br J Dermatol 2021; 184: 464-472. DOI:

Mahe E, Bursztejn AC, Phan A, Corgibet F, Beauchet A. Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists. Dermatol Ther 2018; 31: doi: 10.1111/dth.12567. DOI:

Dogra S, Mahajan R. Biologics in pediatric psoriasis - efficacy and safety. Expert Opin Drug Saf 2018; 17: 9-16. DOI:

Aslam N, Saleem H, Murtazaliev S, Quazi SJ, Khan S. FDA Approved biologics: can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric/adolescents in moderate to severe psoriasis? A systematic review. Cureus 2020; 12: e9812. DOI:



How to Cite

Seyger, M. M., Augustin, M., Sticherling, M., Bachhuber, T., Fang, J., Hetherington, J., Lucas, J., Meakin, S., Richardson, C., & Paller, A. S. (2022). Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study. Acta Dermato-Venereologica, 102, adv00660.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>